Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2023-02 · 21 (2) · 181-209
DOI: 10.6004/jnccn.2023.0006 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2023-02. Verfasst von Nadeem Abu-Rustum und 36 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center. Hauptthemen laut MEDLINE: Adenocarcinoma, Clear Cell, Carcinoma, Endometrioid, Carcinosarcoma, Endometrial Neoplasms. Die Arbeit wurde bisher 515-mal zitiert (Crossref) und nennt 302 Literaturangaben.
Abstract (Originalsprache)
Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, with 12,550 deaths resulting from the disease. Endometrial carcinoma includes pure endometrioid cancer and carcinomas with high-risk endometrial histology (including uterine serous carcinoma, clear cell carcinoma, carcinosarcoma [also known as malignant mixed Müllerian tumor], and undifferentiated/dedifferentiated carcinoma). Stromal or mesenchymal sarcomas are uncommon subtypes accounting for approximately 3% of all uterine cancers. This selection from the NCCN Guidelines for Uterine Neoplasms focuses on the diagnosis, staging, and management of pure endometrioid carcinoma. The complete version of the NCCN Guidelines for Uterine Neoplasms is available online at NCCN.org .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center.
- UC San Diego Moores Cancer Center.
- O'Neal Comprehensive Cancer Center at UAB.
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
- University of Wisconsin Carbone Cancer Center.
- UC Davis Comprehensive Cancer Center.
Zitieren
APA
Abu-Rustum, N., Yashar, C., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S. M., Chino, J., Chon, H. S., Chu, C., Crispens, M. A., Damast, S., Fisher, C. M., Frederick, P., Gaffney, D. K., Giuntoli, R., Han, E., Holmes, J., Howitt, B. E., …, & Aggarwal, S. (2023). Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21(2), 181-209. https://doi.org/10.6004/jnccn.2023.0006
Vancouver
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, et al. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2023;21(2):181-209. doi:10.6004/jnccn.2023.0006
BibTeX
@article{AbuRustum2023,
author = {Abu-Rustum, Nadeem and Yashar, Catheryn and Arend, Rebecca and Barber, Emma and Bradley, Kristin and Brooks, Rebecca and Campos, Susana M and Chino, Junzo and Chon, Hye Sook and Chu, Christina and Crispens, Marta Ann and Damast, Shari and Fisher, Christine M and Frederick, Peter and Gaffney, David K and Giuntoli, Robert and Han, Ernest and Holmes, Jordan and Howitt, Brooke E and Lea, Jayanthi and Mariani, Andrea and Mutch, David and Nagel, Christa and Nekhlyudov, Larissa and Podoll, Mirna and Salani, Ritu and Schorge, John and Siedel, Jean and Sisodia, Rachel and Soliman, Pamela and Ueda, Stefanie and Urban, Renata and Wethington, Stephanie L and Wyse, Emily and Zanotti, Kristine and McMillian, Nicole R and Aggarwal, Shaili},
title = {Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2023},
volume = {21},
number = {2},
pages = {181--209},
doi = {10.6004/jnccn.2023.0006}
}
EUVIMED